↓ Skip to main content

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Overview of attention for article published in Future Oncology, February 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
4 X users
patent
1 patent
video
1 YouTube creator
podcasts
1 podcast

Readers on

mendeley
164 Mendeley